Anti-IgE therapy in allergic disease

Current Opinion in Pediatrics

Volumn 16, Issue 6, 2004, Pages 642-647

  Milgrom, Henry ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Allergy; Anti IgE; Fc RI; Recombinant monoclonal antibody

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FC RECEPTOR; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; NEDOCROMIL; PREDNISONE; SALBUTAMOL; SALMETEROL;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; DRUG EFFICACY; FOOD ALLERGY; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; HYPERSENSITIVITY; MIDDLE AGED;

EID: 9244255323     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000145918.92477.16     Document Type: Review

References (60)

1. Oettgen HC, Geha RS: IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999, 104:829-835.
2. Busse WW, Lemanske RF Jr: Asthma. N Engl J Med 2001, 344:350-362.
3. Bradding P, Roberts JA, Britten KM, et al.: Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994, 10:471-480.
4. Pawankar RU, Okuda M, Hasegawa S, et al.: Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis. Am J Respir Crit Care Med 1995, 152:2059-2067.
5. Williams CM, Galli SJ: Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000, 192:455-462.
6. Kobayashi T, Miura T, Haba T, et al.: An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol 2000, 164:3855-3861.
7. Kawakami T, Galli SJ: Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002, 2:773-786.
8. Asai K, Kitaura J, Kawakami Y, et al.: Regulation of mast cell survival by IgE. Immunity 2001, 14:791-800.
9. Kitaura J, Song J, Tsai M, et al.: Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcεRI. Proc Natl Acad Sci U S A 2003, 100:12911-12916. The binding of various IgE molecules by mast cells induces cell activation in the absence of antigen.
10. Williams CM, Galli SJ: The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 2000, 105:847-859.
11. Shields RL, Whether WR, Zioncheck K, et al.: Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995, 107:308-312.
12. Coyle AJ, Wagner K, Bertrand C, et al.: Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphyl actogenic anti-IgE antibody. J Exp Med 1996, 183:1303-1310.
13. MacGlashan DW Jr, Bochner BS, Adelman DC, et al.: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997, 158:1438-1445.
14. Prussin C, Griffith DT, Boesel KM, et al.: Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003, 112:1147-1154. Treatment with anti-IgE is associated with a decrease in cell-surface FcεRI expression on dendrtitic cells. The decrease in FcεRI expression correlates with the decrease in IgE.
15. Fahy J, Fleming H, Wong H, et al.: The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997, 155:1828-1834.
16. Djukanovic R, Wilson SJ, Kraft M, et al.: The effects of anti-IgE (omalizumab) on airways inflammation in allergic asthma. Am J Respir Crit Care Med 2004. Published on June 1, 2004 as doi:10.1164/rccm.200312-1651OC. Treatment with anti-IgE decreases IgE in the airway mucosa of asthmatics. It is associated with a marked reduction in airway eosinophilia, expression of FcεRI, and IL-4. Interestingly, these changes are not accompanied by a measurable improvement in airway hyperresponsiveness.
17. Stein RT, Sherrill D, Morgan WJ, et al.: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354:541-545.
18. Stein RT, Martinez FD: Asthma phenotypes in childhood: lessons from an epidemiological approach. Paediatr Respir Rev 2004, 5:155-161.
19. Payne D, Bush A: Phenotype-specific treatment of difficult asthma in children. Paediatr Respir Rev 2004, 5:116-123.
20. Bush A: Phenotype specific treatment of asthma in childhood. Paediatr Respir Rev 2004, 5(suppl A):S93-S101.
21. Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ: Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987, 79:653-659.
22. Waalkens HJ, Van Essen-Zandvliet EE, Hughes MD, et al.: Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group. Am Rev Respir Dis 1993, 148:1252-1257.
23. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al.: Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group. Eur Respir J 1994, 7:63-68.
24. Ulrik CS, Backer V: Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999, 14:892-896.
25. Szefler SJ, Martin RJ, King TS, et al.: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002, 109:410-418.
26. The Childhood Asthma Management Program Research Group: Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000, 343:1054-1063.
27. 1 (thought to reflect remodeling) in adolescent patients.
28. Bateman ED, Bousquet J, Braunstein GL: Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001, 17:589-595.
29. Roth M, Johnson PR, Borger P, et al.: Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med 2004, 351:560-574. Antiproliferative and cytokine-inhibiting effects of corticosteroids are mediated by distinct pathways. The absence of C/EBP may be responsible for the enhanced proliferation and failure to respond to steroids by bronchial smooth muscle cells of patients with asthma. Interestingly, C/EBP is normally expressed and antiproliferative activity is preserved in bronchial smooth muscle cells from subjects with emphysema.
30. Holt PG, Sly PD: Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs. Thorax 2000, 55:700-703.
31. Boulet L, Chapman K, Cote J, et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997, 155:1835-1840.
32. Milgrom H, Fick RB Jr, Su JQ, et al.: Treatment of allergic asthma with monoclonal anti-IgE antibody, rhuMAb-E25 Study Group. N Engl J Med 1999, 341:1966-1973.
33. Busse W, Corren J, Lanier BQ, et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190.
34. Soler M, Matz J, Townley R, et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261.
35. Corren J, Casale T, Deniz Y, Ashby M: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003, 111:87-90.
36. Walker S, Monteil M, Phelan K, et al.: Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2004, 3:CD003559. The authors call for further studies in pediatric and adult patients with severe disease and for double-dummy comparison of effectiveness against ICS.
37. Holgate ST, Chuchalin AG, Hebert J, et al.: Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-638. This study, conducted in patients with severe allergic asthma, shows that anti-IgE is well tolerated as an adjunct to optimized therapy with ICS. The addition of anti-IgE reduces the requirement for ICS and rescue medication and improves asthma symptoms and asthma-related QoL.
38. Milgrom H, Berger W, Nayak A, et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001, 108:E36.
39. NO fell significantly during 1 year of continuous treatment with anti-IgE despite a marked decline or discontinuation of corticosteroid therapy.
40. Adelroth E, Rak S, Haahtela T, et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000, 106:253-259.
41. Casale TB: Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis. J Allergy Clin Immunol 2001, 108:384-388.
42. Chervinsky P, Casale T, Townley R, et al.: Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003, 91:160-167.
43. Lin H, Boesel KM, Griffith DT, et al.: Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004, 113:297-302. Anti-IgE rapidly inhibited ragweed-induced nasal responses. The inhibition was demonstrated at 7 to 14 days but was more pronounced at 35 to 42 days.
44. Hanf G, Noga O, O'Connor A, Kunkel G: Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 2004, 23:414-418. A significant decrease in albumin after allergen challenge was observed in the nasal lavage of subjects treated with anti-IgE. Albumin concentration in the nasal lavage reflects vascular permeability.
45. Sampson HA: Update on food allergy. J Allergy Clin Immunol 2004, 113:805-819.
46. Leung DY, Sampson HA, Yunginger JW, et al.: Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003, 348:986-993. This multicenter, double-blind, randomized, placebo-controlled study investigated 84 patients with a known immediate hypersensitivity response to peanut. Patients received placebo or anti-IgE subcutaneously every 4 weeks for four doses. They underwent a final oral food challenge 2 to 4 weeks after the fourth dose. The highest dose of anti-IgE provided protection against an ingestion equivalent to nine peanuts.
47. Sicherer SH, Leung DY: Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insect stings. J Allergy Clin Immunol 2004, 114:118-124.
48. Castro-Rodriguez JA, Stern DA, Halonen M, et al.: Relation between infantile colic and asthma/atopy: a prospective study in an unselected population. Pediatrics 2001, 108:878-882.
49. Basso AS, Pinto FA, Russo M, et al.: Neural correlates of IgE-mediated food allergy. J Neuroimmunol 2003, 140:69-77. There is definitely an association between perceived food intolerance and psychiatric disorders in patients with allergies, but nobody knows its significance. An animal model to study these phenomena might fill this gap.
50. Novak N, Tepel C, Koch S, et al.: Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors. J Clin Invest 2003, 111:1047-1056. The intracellular α chain of the FcεRI (FcεRIα) accumulates during the differentiation of dendrititic cells from monocytes while γ chains required for surface expression are downregulated.
51. Semper AE, Heron K, Woollard AC, et al.: Surface expression of Fc epsilon RI on Langerhans' cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma, and rhinitis. J Allergy Clin Immunol 2003, 112:411-419. Langerhans' cells from all individuals, regardless of atopic status, have demonstrable cytoplasmic FcεRIα, while membrane expression of FcεRI is linked to active allergic disease. The authors propose that the most likely cause of the expression of FcRI on the surface of Langerhans' cells is the upregulation of the γ chain induced by an unknown mechanism.
52. Kuehr J, Brauburger J, Zielen S, et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:274-280.
53. Hamelmann E, Rolinck-Werninghaus C, Wahn U: Is there a role for anti-IgE in combination with specific allergen immunotherapy? Curr Opin Allergy Clin Immunol 2003, 3:501-510.
54. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al.: The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004, 59:973-979.
55. Bez C, Schubert R, Kopp M, et al.: Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004, 34:1079-1085.
56. Drazen JM, Silverman EK, Lee TH: Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000, 56:1054-1070.
57. Bousquet J, Wenzel S, Holgate S, et al.: Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004, 125:1378-1386. The ability to identify patients most likely to benefit from anti-IgE therapy is indispensable. Bousquet et al. report the results of a pooled exploratory analysis to characterize such patients. In their analysis they accounted for the large placebo response observed in the two original studies.
58. Sher ER, Leung DY, Surs W, et al.: Steroid-resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994, 93:33-39.
59. Milgrom H, Bender B: Nonadherence to asthma treatment and failure of therapy. Curr Opin Pediatr 1997, 9:590-595.
60. Milgrom H, Bender B, Ackerson L, et al.: Non-compliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996, 98:1051-1057.